ALB and neoplasm: Additionally, most available studies on the prognostic role of albumin levels in ICI-treated patients have limited or absent data regarding previously established ICI-efficacy biomarkers like PD-L1 and tumor mutational burden levels (Davis and Patel, 2019; Xu et al., 2019; Huang et al., 2021).